If the glycoprotein concentration in urine samples from bladder cancer patients is confirmed as significantly greater than the concentration in control samples then a more streamlined assay such as a sandwich ELISA combining lectin and antibody binding would be required for full validation and ultimately clinical use. The gene discussed is ART4; the disease is urinary bladder carcinoma.